MX375266B - Compuestos y su uso. - Google Patents

Compuestos y su uso.

Info

Publication number
MX375266B
MX375266B MX2017008882A MX2017008882A MX375266B MX 375266 B MX375266 B MX 375266B MX 2017008882 A MX2017008882 A MX 2017008882A MX 2017008882 A MX2017008882 A MX 2017008882A MX 375266 B MX375266 B MX 375266B
Authority
MX
Mexico
Prior art keywords
compounds
formula
lactamases
restore
inhibitors
Prior art date
Application number
MX2017008882A
Other languages
English (en)
Inventor
Aravind Appu
Gopalan Balasubramanian
Hariharan Periasamy
Maneesh Paul-Satyaseela
Senthilkumar Udayampalayam Palanisamy
Senthilnathan Manickam
Shridhar Narayanan
Original Assignee
Allecra Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45757037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX375266(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allecra Therapeutics Gmbh filed Critical Allecra Therapeutics Gmbh
Publication of MX375266B publication Critical patent/MX375266B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/88—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/883—Compounds with a double bond between positions 2 and 3 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with a substituted hydrocarbon radical attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente invención se describen compuestos y su uso en el tratamiento de infecciones. El compuesto de la fórmula (I), sus derivados, análogos, formas tautoméricas, estereoisómeros, polimorfos, solvatos, sales farmacéuticamente aceptables y composiciones farmacéuticas aquí descritas, también son útiles como inhibidores de ß-lactamasa, que restauran o incrementan el espectro antibiótico de un agente antibiótico adecuado. Los compuestos de la fórmula (I) actúan como inhibidores de ß-lactamasas. Estos compuestos restauran/potencian las actividades de los antibióticos de ß-lactam contra carbapenemasas. Estos compuestos encuentran uso en el método de diagnóstico para detectar ß-lactamasas. Fórmula (I).
MX2017008882A 2010-11-25 2011-11-25 Compuestos y su uso. MX375266B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3555CH2010 2010-11-25
IN3096CH2011 2011-09-09
PCT/IN2011/000813 WO2012070071A1 (en) 2010-11-25 2011-11-25 Compounds and their use

Publications (1)

Publication Number Publication Date
MX375266B true MX375266B (es) 2025-03-06

Family

ID=45757037

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017008882A MX375266B (es) 2010-11-25 2011-11-25 Compuestos y su uso.
MX2013005907A MX353447B (es) 2010-11-25 2011-11-25 Compuestos y su uso.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013005907A MX353447B (es) 2010-11-25 2011-11-25 Compuestos y su uso.

Country Status (30)

Country Link
US (1) US10201532B2 (es)
EP (1) EP2642992B1 (es)
JP (1) JP5961177B2 (es)
KR (1) KR101933084B1 (es)
CN (2) CN103347515B (es)
AP (1) AP2013006947A0 (es)
AU (1) AU2011333305B2 (es)
BR (1) BR112013012735B1 (es)
CA (1) CA2818100C (es)
CL (1) CL2013001482A1 (es)
CO (1) CO6781486A2 (es)
CR (1) CR20130306A (es)
DK (1) DK2642992T3 (es)
EA (1) EA030662B1 (es)
EC (1) ECSP13012716A (es)
ES (1) ES2859639T3 (es)
FR (1) FR24C1035I2 (es)
HU (1) HUE053623T2 (es)
IL (1) IL226538A (es)
MA (1) MA34760B1 (es)
MX (2) MX375266B (es)
MY (1) MY170435A (es)
NZ (1) NZ610247A (es)
PE (1) PE20140716A1 (es)
PH (1) PH12013501042A1 (es)
SG (1) SG190877A1 (es)
SV (1) SV2013004451A (es)
UA (1) UA115966C2 (es)
WO (1) WO2012070071A1 (es)
ZA (1) ZA201303773B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2993900B1 (fr) * 2012-07-27 2016-03-25 Biomerieux Sa Procede de detection de bacteries productrices de carbapenemases de type oxa-48
TW201922795A (zh) * 2012-09-10 2019-06-16 愛爾蘭商尼歐托普生物科學公司 抗ｍｃａｍ抗體及相關使用方法
US20140128364A1 (en) * 2012-11-05 2014-05-08 Rempex Pharmaceuticals Therapeutic uses of tigemonam and carumonam
GB201319776D0 (en) * 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
GB201408649D0 (en) * 2014-05-15 2014-07-02 Allecra Therapeutics Sas Method
JP2016010399A (ja) * 2014-06-03 2016-01-21 日水製薬株式会社 カルバペネマーゼ産生耐性菌検出用組成物
FR3024465B1 (fr) * 2014-07-30 2018-03-23 Biomerieux Caracterisation de micro-organismes par maldi-tof
EP3372587A1 (en) * 2017-03-09 2018-09-12 Centre National de la Recherche Scientifique (CNRS) 3-imidazolines as carbapenemases inhibitors
SI25892A (sl) * 2019-09-05 2021-03-31 Gorenje Gospodinjski Aparati, D.O.O. Pralni stroj, ki se polni s sprednje strani, z električnim svetlobnim telesom
EP4028404A4 (en) * 2019-09-11 2023-07-26 Tennor Therapeutics (Suzhou) Limited PENAM DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS
CN110840897B (zh) * 2019-11-28 2023-08-08 河北旺发生物科技有限公司 金属β-内酰胺酶抑制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59118790A (ja) * 1982-12-24 1984-07-09 Taiho Yakuhin Kogyo Kk ペニシリン誘導体
US4562073A (en) 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
JPS60215688A (ja) * 1984-04-09 1985-10-29 Taiho Yakuhin Kogyo Kk ペニシリン誘導体
US4891369A (en) 1986-12-03 1990-01-02 Taiho Pharmaceutical Company, Limited 2β-Substituted-methylpenicillanic acid derivatives, and salts and esters thereof
JP2599595B2 (ja) * 1987-06-26 1997-04-09 大鵬薬品工業株式会社 ２β−置換メチルペニシラン酸誘導体、その塩及びエステル
JP2648750B2 (ja) * 1988-03-02 1997-09-03 大塚化学株式会社 β−ラクタム誘導体の製造方法
ES2298672T3 (es) 2003-04-14 2008-05-16 Wyeth Holdings Corporation Composiciones que contienen piperacilina y tazobactam utiles para inyeccion.
KR20070110256A (ko) 2004-10-14 2007-11-16 와이어쓰 유산나트륨 희석제 내에 피페라실린, 타조박탐 및아미노카르복실산을 함유하는 조성물
SI2046802T1 (sl) * 2006-07-12 2014-03-31 Allecra Therapeutics Gmbh C/O Loeba Treuhand Gmbh 2-substituirani metil penamski derivati
FR2936951B1 (fr) 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments

Also Published As

Publication number Publication date
CN103347515A (zh) 2013-10-09
HUE053623T2 (hu) 2021-07-28
UA115966C2 (uk) 2018-01-25
CN107260729A (zh) 2017-10-20
AP2013006947A0 (en) 2013-06-30
US20140057888A1 (en) 2014-02-27
WO2012070071A1 (en) 2012-05-31
BR112013012735A8 (pt) 2021-10-26
JP5961177B2 (ja) 2016-08-02
NZ610247A (en) 2014-09-26
MX2013005907A (es) 2013-12-06
KR20140052927A (ko) 2014-05-07
CA2818100A1 (en) 2012-05-31
BR112013012735B1 (pt) 2021-11-23
ES2859639T3 (es) 2021-10-04
CO6781486A2 (es) 2013-10-31
CN103347515B (zh) 2017-06-06
CA2818100C (en) 2019-07-09
BR112013012735A2 (pt) 2017-11-07
MX353447B (es) 2018-01-11
MY170435A (en) 2019-07-31
EA030662B1 (ru) 2018-09-28
PE20140716A1 (es) 2014-07-12
CR20130306A (es) 2013-09-18
KR101933084B1 (ko) 2018-12-28
FR24C1035I2 (fr) 2025-05-30
EP2642992B1 (en) 2020-11-25
MA34760B1 (fr) 2013-12-03
CN107260729B (zh) 2020-03-31
SG190877A1 (en) 2013-07-31
ECSP13012716A (es) 2013-08-30
DK2642992T3 (da) 2021-03-01
JP2014504279A (ja) 2014-02-20
IL226538A (en) 2017-07-31
ZA201303773B (en) 2014-11-26
EP2642992A1 (en) 2013-10-02
WO2012070071A9 (en) 2012-08-16
FR24C1035I1 (fr) 2024-12-06
SV2013004451A (es) 2017-12-01
AU2011333305B2 (en) 2017-06-22
PH12013501042A1 (en) 2021-06-02
CL2013001482A1 (es) 2014-04-04
EA201300617A1 (ru) 2014-03-31
AU2011333305A1 (en) 2013-07-11
US10201532B2 (en) 2019-02-12

Similar Documents

Publication Publication Date Title
MX375266B (es) Compuestos y su uso.
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
MX2010001754A (es) Derivados de azepina como inhibidores de gamma secretasa.
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
UY30759A1 (es) Compuestos quimicos
MX2011011136A (es) Eteres diarilicos.
CO6382176A2 (es) Derivados de urea heterociclicos y metodos de uso de los mismos-332
ECSP10010659A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
MX341342B (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.
MX2013007892A (es) Derivados de fenetilsulfona isoindolina y su uso.
UY32694A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
TN2013000221A1 (en) Compounds and their use
TH143302A (th) สารประกอบ และการใช้ของสารเหล่านั้น
CU20100237A7 (es) Derivados heterocíclicos de la urea y sus métodos de empleo
CU20100172A7 (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
CU20100239A7 (es) Derivados de urea heterocíclicos para el tratamiento de las infecciones bacterianas